345 related articles for article (PubMed ID: 23999928)
1. Epigenetic susceptibility factors for prostate cancer with aging.
Damaschke NA; Yang B; Bhusari S; Svaren JP; Jarrard DF
Prostate; 2013 Dec; 73(16):1721-30. PubMed ID: 23999928
[TBL] [Abstract][Full Text] [Related]
2. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.
Fu VX; Dobosy JR; Desotelle JA; Almassi N; Ewald JA; Srinivasan R; Berres M; Svaren J; Weindruch R; Jarrard DF
Cancer Res; 2008 Aug; 68(16):6797-802. PubMed ID: 18701505
[TBL] [Abstract][Full Text] [Related]
3. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
4. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
5. Tissue-, sex-, and age-specific DNA methylation of rat glucocorticoid receptor gene promoter and insulin-like growth factor 2 imprinting control region.
Agba OB; Lausser L; Huse K; Bergmeier C; Jahn N; Groth M; Bens M; Sahm A; Gall M; Witte OW; Kestler HA; Schwab M; Platzer M
Physiol Genomics; 2017 Nov; 49(11):690-702. PubMed ID: 28916632
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
7. Loss of
Damaschke NA; Yang B; Bhusari S; Avilla M; Zhong W; Blute ML; Huang W; Jarrard DF
Cancer Res; 2017 Oct; 77(19):5236-5247. PubMed ID: 28775169
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.
Bhusari S; Yang B; Kueck J; Huang W; Jarrard DF
Prostate; 2011 Nov; 71(15):1621-30. PubMed ID: 21432864
[TBL] [Abstract][Full Text] [Related]
9. A methyl-deficient diet modifies histone methylation and alters Igf2 and H19 repression in the prostate.
Dobosy JR; Fu VX; Desotelle JA; Srinivasan R; Kenowski ML; Almassi N; Weindruch R; Svaren J; Jarrard DF
Prostate; 2008 Aug; 68(11):1187-95. PubMed ID: 18459101
[TBL] [Abstract][Full Text] [Related]
10. Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.
Ribarska T; Bastian KM; Koch A; Schulz WA
Asian J Androl; 2012 May; 14(3):436-50. PubMed ID: 22367183
[TBL] [Abstract][Full Text] [Related]
11. Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
Wang H; Ge S; Qian G; Li W; Cui J; Wang G; Hoffman AR; Hu JF
Exp Cell Res; 2015 Nov; 338(2):214-21. PubMed ID: 26407907
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modifications in prostate cancer.
Sugiura M; Sato H; Kanesaka M; Imamura Y; Sakamoto S; Ichikawa T; Kaneda A
Int J Urol; 2021 Feb; 28(2):140-149. PubMed ID: 33111429
[TBL] [Abstract][Full Text] [Related]
13. Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
Zhao X; Liu X; Wang G; Wen X; Zhang X; Hoffman AR; Li W; Hu JF; Cui J
Oncotarget; 2016 Aug; 7(32):51349-51364. PubMed ID: 27275535
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma.
Ribarska T; Ingenwerth M; Goering W; Engers R; Schulz WA
Cancer Genomics Proteomics; 2010; 7(2):51-60. PubMed ID: 20335518
[TBL] [Abstract][Full Text] [Related]
15. Imprinting of the mouse Igf2r gene depends on an intronic CpG island.
Wutz A; Barlow DP
Mol Cell Endocrinol; 1998 May; 140(1-2):9-14. PubMed ID: 9722161
[TBL] [Abstract][Full Text] [Related]
16. IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch.
Li T; Vu TH; Ulaner GA; Littman E; Ling JQ; Chen HL; Hu JF; Behr B; Giudice L; Hoffman AR
Mol Hum Reprod; 2005 Sep; 11(9):631-40. PubMed ID: 16219628
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.
Küffer S; Gutting T; Belharazem D; Sauer C; Michel MS; Marx A; Trojan L; Ströbel P
Mol Oncol; 2018 Feb; 12(2):256-266. PubMed ID: 29239100
[TBL] [Abstract][Full Text] [Related]
18. Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
Savio AJ; Bapat B
Methods Mol Biol; 2015; 1238():103-24. PubMed ID: 25421657
[TBL] [Abstract][Full Text] [Related]
19. In-utero stress and mode of conception: impact on regulation of imprinted genes, fetal development and future health.
Argyraki M; Damdimopoulou P; Chatzimeletiou K; Grimbizis GF; Tarlatzis BC; Syrrou M; Lambropoulos A
Hum Reprod Update; 2019 Nov; 25(6):777-801. PubMed ID: 31633761
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation of the IGF2/H19 imprinted domain in human embryonic and extra-embryonic compartments and its possible role in fetal growth restriction.
Tabano S; Colapietro P; Cetin I; Grati FR; Zanutto S; Mandò C; Antonazzo P; Pileri P; Rossella F; Larizza L; Sirchia SM; Miozzo M
Epigenetics; 2010 May; 5(4):313-24. PubMed ID: 20418667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
